• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[孕期宫颈和阴道中胎儿纤连蛋白的水平]

[Levels of fetal fibronectin in the cervix and vagina during pregnancy].

作者信息

Novakov-Mikić A, Ivanović L, Nikolić A, Dukanac J, Crnogorac Z

机构信息

Klinicki centar Novi Sad, Klinika za ginekologiju i akuserstvo, Medicinski fakultet.

出版信息

Med Pregl. 1999 Nov-Dec;52(11-12):441-5.

PMID:10748765
Abstract

INTRODUCTION

Fibronectin is a glycoprotein produced by different types of cells. It can be divided into two main groups--soluble fibronectin, found in human plasma and other body fluids (amniotic fluid) and tissue fibronectin, found in basal membrane and connective tissue between endothelial cells (2). There are three subtypes--plasmatic, cellular and onco-fetal fibronectin, the most important during pregnancy, with different concentrations during the course of pregnancy. The aim of the study is to establish normal distribution of fetal fibronectin in cervicovaginal fluid during pregnancy in our population and afterwards establish the relation between concentrations in different stages of pregnancy and the pregnancy outcome.

MATERIAL AND METHODS

This prospective, observational study was done at the Department of Obstetrics and Gynaecology, Clinical Centre Novi Sad, during the period June-October 1988. The presented results are preliminary ones. The patients were randomly chosen from the population that came for routine consultations as well as the ones hospitalized at the Department, at the High Risk Pregnancy Unit, for reasons other than threatening miscarriage and preterm delivery. One-hundred and thirty two pregnant women were examined, divided into three groups, according to gestational age. In group I were women between 7-20 weeks, in group II between 21 and 37 weeks and in group III 38 and more weeks. In every case general and obstetric data were collected, and cervico-vaginal fibronectin was taken from the posterior vaginal fornix, using a special kit (Specimen Collection Package, Adeza Biomedical). Fetal fibronectin concentration was tested using enzyme immunoassay (Adeza Biomedical) and positive was considered the concentration of and above 0.05 microgram/ml.

RESULTS

The mean cervico-vaginal fibronectin concentration, uncorrected for the outcome of the pregnancy was as follows--in group I 0.045 (0-0.11) microgram/ml, group II 0.037 (0-1.22) microgram/ml, and in group III 0.226 (0.001-1.05) microgram/ml. The concentration trend was from weakly negative during the period 7-20 weeks, over highly negative (21-37 weeks) to very positive, after 38 weeks. The positive/negative relation in group I was 29.2%/70.8%, group II 11.7%/88.3% and group III 48.4%%/51.6%. After the correction of the results for miscarriages/preterm deliveries/failed induction in postterm pregnancies, the mean concentrations were somewhat different--group I 0.029 microgram/ml, II 0.019 microgram/ml and III 0.282 microgram/ml. The relations of positive and negative results were changed as well and in group I the relation was 27.3%/72.7%, group II 6.8%/93.2% and group III 71.4%/28.6%.

DISCUSSION

After the correction for duration and outcome of the pregnancy, our results differed from the results in the literature. Thus in the 1st trimester fetal fibronectin was positive in cervico-vaginal fluid of 27.3% pregnant women, which is double the number usually found in the literature, between 21 and 37 weeks, when a positive result (> 0.05 microgram/ml) would be expected in only 3% of cases, it was positive in 6.8%, whereas 2.3 of the women delivered at term had a positive concentration. The discrepancy in group II (21-37 weeks) cannot be explained neither with a higher incidence of late miscarriages, nor preterm deliveries, for the incidence of such complications was only 3%, which is far less than usually found in the non-selected population (10%) (9). It is also possible that the discrepancy in our results and the results found in literature is based on a fact that our population was not preselected, which was the case in other studies' populations that did not include women with heavy, non-treated vaginal discharge, nor the ones that had sexual intercourse within 24 hours from the moment of fibronectin sampling. (ABSTRACT TRUNCATED)

摘要

引言

纤连蛋白是一种由不同类型细胞产生的糖蛋白。它可分为两大类——可溶性纤连蛋白,存在于人体血浆和其他体液(羊水)中;组织纤连蛋白,存在于基底膜和内皮细胞之间的结缔组织中(2)。有三种亚型——血浆型、细胞型和癌胚型纤连蛋白,其中癌胚型纤连蛋白在孕期最为重要,在孕期过程中浓度各异。本研究的目的是确定我们人群中孕期宫颈阴道液中胎儿纤连蛋白的正常分布,进而确定孕期不同阶段其浓度与妊娠结局之间的关系。

材料与方法

这项前瞻性观察性研究于1988年6月至10月在诺维萨德临床中心妇产科进行。所呈现的结果为初步结果。患者从前来进行常规会诊的人群以及因非先兆流产和早产原因而入住该科高危妊娠病房的患者中随机选取。共检查了132名孕妇,根据孕周分为三组。第一组为孕7至20周的妇女,第二组为孕21至37周的妇女,第三组为孕38周及以上的妇女。每种情况下均收集一般和产科数据,并使用专用试剂盒(标本采集包,阿德扎生物医学公司)从阴道后穹窿采集宫颈阴道纤连蛋白。采用酶免疫测定法(阿德扎生物医学公司)检测胎儿纤连蛋白浓度,浓度≥0.05微克/毫升被视为阳性。

结果

未根据妊娠结局校正的宫颈阴道纤连蛋白平均浓度如下——第一组为0.045(0 - 0.11)微克/毫升,第二组为0.037(0 - 1.22)微克/毫升,第三组为0.226(0.001 - 1.05)微克/毫升。浓度趋势从孕7至20周时弱阳性,经孕21至37周时高度阴性,至孕38周后呈强阳性。第一组的阳性/阴性比例为29.2%/70.8%,第二组为11.7%/88.3%,第三组为48.4%/51.6%。在校正流产/早产/过期妊娠引产失败的结果后,平均浓度略有不同——第一组为0.029微克/毫升,第二组为0.019微克/毫升,第三组为0.282微克/毫升。阳性和阴性结果的比例也发生了变化,第一组的比例为27.3%/72.7%,第二组为6.8%/93.2%,第三组为71.4%/28.6%。

讨论

在校正妊娠持续时间和结局后,我们的结果与文献中的结果不同。因此,在孕早期,27.3%孕妇的宫颈阴道液中胎儿纤连蛋白呈阳性,这是文献中通常发现数量的两倍;在孕21至37周时,预期只有3%的病例会出现阳性结果(>0.05微克/毫升),而实际阳性率为6.8%,足月分娩的妇女中有2.3%的人纤连蛋白浓度呈阳性。第二组(孕21至37周)的差异既不能用晚期流产或早产发生率较高来解释,因为此类并发症的发生率仅为3%,远低于未选择人群中的通常发生率(10%)(9)。我们的结果与文献结果存在差异也可能是因为我们的人群未经过预先筛选,而其他研究的人群则经过筛选,不包括患有严重、未治疗的阴道分泌物的妇女,也不包括在采集纤连蛋白样本后24小时内有过性交的妇女。(摘要截断)

相似文献

1
[Levels of fetal fibronectin in the cervix and vagina during pregnancy].[孕期宫颈和阴道中胎儿纤连蛋白的水平]
Med Pregl. 1999 Nov-Dec;52(11-12):441-5.
2
[Presence of fetal fibronectin in cervico-vaginal secretion as predictor of premature labor].
Ginecol Obstet Mex. 1999 Jan;67:23-8.
3
Preterm delivery: predictive value of cervico-vaginal fetal fibronectin.
Clin Exp Obstet Gynecol. 1999;26(3-4):187-9.
4
Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery.宫颈和阴道分泌物中的胎儿纤连蛋白作为早产的预测指标
N Engl J Med. 1991 Sep 5;325(10):669-74. doi: 10.1056/NEJM199109053251001.
5
[Fetal fibronectin in cervico-vaginal secretions--an indicator of incipient premature labor using a membrane immunoassay].
Ceska Gynekol. 1995 Dec;60(6):293-5.
6
[Reliability of the detection of fetal fibronectin using monoclonal antibody FDC-6].[使用单克隆抗体FDC-6检测胎儿纤连蛋白的可靠性]
Geburtshilfe Frauenheilkd. 1995 Dec;55(12):703-6. doi: 10.1055/s-2007-1022318.
7
The frequency and clinical significance of intra-amniotic inflammation in patients with a positive cervical fetal fibronectin.宫颈胎儿纤连蛋白检测呈阳性的患者羊膜腔内炎症的发生率及临床意义。
Am J Obstet Gynecol. 2001 Nov;185(5):1137-42. doi: 10.1067/mob.2001.118162.
8
A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study.甲硝唑预防宫颈阴道胎儿纤连蛋白阳性女性早产的随机对照试验:PREMET研究
BJOG. 2006 Jan;113(1):65-74. doi: 10.1111/j.1471-0528.2005.00788.x.
9
The presence of fetal fibronectin in the cervicovaginal secretions of women at term--its role in the assessment of women before labor induction and in the investigation of the physiologic mechanisms of labor.足月孕妇宫颈阴道分泌物中胎儿纤维连接蛋白的存在——其在引产术前评估孕妇及分娩生理机制研究中的作用。
Am J Obstet Gynecol. 1996 Jan;174(1 Pt 1):262-6. doi: 10.1016/s0002-9378(96)70405-2.
10
[Ultrasonographic assessment of cervical length and measurement of fetal fibronectin level in cervical secretion of pregnant women in prophylaxis of premature deliveries].
Ginekol Pol. 2001 Dec;72(12):1139-43.